InMed Pharmaceuticals  logo
InMed Pharmaceuticals INM
$ 0.66 -3.71%

Quarterly report 2025-Q4
added 02-11-2026

report update icon

InMed Pharmaceuticals Financial Statements 2011-2026 | INM

Annual Financial Statements InMed Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.71 M 3.02 M 269 K 46.7 M - - - - - - - - -

Shares

2.45 M 561 K 269 K 5.22 M - - - - - - - - -

Historical Prices

0.7 5.39 1.21 4.21 8.91 16.1 31.3 8.48 4.29 2.97 - - -

Net Income

-7.95 M -18.6 M -10.2 M -11.9 M -13.3 M -8.52 M -4.47 M -2.38 M -4.29 M -1.23 M -49.2 K -193 K -315 K

Revenue

4.14 M 1.09 M 1.9 M - - - - - - - - - 38.4 K

Cost of Revenue

2.42 M 546 K - - - - - - - - - - -

Gross Profit

1.4 M 544 K - - - - - - - - - - 38.4 K

Operating Income

-7.95 M -18.6 M -10.2 M - - - - - - - - - -

Interest Expense

431 K -1.34 M -360 K - - - - - - - - - -

EBITDA

-7.75 M -18.4 M -10.1 M -11.9 M -13.5 M -8.49 M -4.38 M -2.29 M -4.2 M -1.23 M -49.2 K -171 K -244 K

Operating Expenses

9.78 M 17.8 M 9.94 M 8.87 M 10.4 M 6.55 M 3.44 M 1.84 M 3.46 M 1.15 M 46.7 K 169 K 427 K

General and Administrative Expenses

369 K 290 K 4.48 M 3.5 M 6 M 4.99 M 2.79 M 1.48 M 2.62 M 1.09 M 46.7 K - 287 K

All numbers in USD currency

Quarterly Income Statement InMed Pharmaceuticals

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

3.95 M 3.95 M 2 M 1.1 M 707 K 620 K 446 K 481 K 399 K 166 K 3.33 M 3.33 M 2.3 M 866 K 651 K 566 K 554 K 482 K 517 K 7.55 M 6.09 M 5.22 M 6.09 M 5.22 M 5.22 M 5.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-2.03 M -1.73 M - -2.12 M -2.58 M -1.68 M - -1.72 M -1.48 M -2.54 M - -2 M -2.1 M -3.51 M -5.61 M -3.48 M -4.28 M -2.97 M -7.25 M -3.1 M -2.24 M -1.6 M -2.24 M -1.6 M -2.49 M -2.81 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

820 K 1.12 M - 1.26 M 1.11 M 1.26 M - 1.17 M 1.24 M 902 K - 1.03 M 470 K 321 K 791 K 310 K 265 K 1.02 M 265 K 437 K 277 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

636 K 717 K - 1.09 M 651 K 771 K - 883 K 916 K 881 K - 841 K 339 K 235 K 574 K 127 K 154 K - 154 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

184 K 403 K - 176 K 461 K 493 K - 289 K 324 K 21.2 K - 193 K 131 K -491 K -360 K 182 K 112 K - 112 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - - - - - - -2 M -2.1 M -3.51 M -5.61 M -3.48 M -4.28 M -2.97 M -7.25 M -3.1 M -2.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - - - -1.5 K -3 K -6.8 K -9.8 K - - -360 K - - -360 K - -360 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - - - -1.95 M -2.05 M -3.46 M -5.51 M -3.42 M -4.23 M -2.94 M -7.18 M -3.07 M -2.21 M 28 K 64.8 K 28 K 28.2 K 30.2 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

2.29 M 2.22 M - 2.31 M 2.71 M 2.23 M - 2.13 M 1.97 M 2.69 M - 2.34 M 2.35 M 2.99 M 5.35 M 3.72 M 4.42 M 2.89 M 7.32 M 3.13 M 1.93 M 1.56 M 1.93 M 1.56 M 2.51 M 2.88 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

1.62 M 1.53 M - 1.33 M 1.72 M 1.49 M - 1.37 M 1.36 M 1.3 M - 1.41 M 44 K 1.56 M 3.03 M 1.92 M 1.84 M 1.37 M 3.21 M 1.33 M 960 K 625 K 960 K 625 K 872 K 888 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements InMed Pharmaceuticals INM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting InMed Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Verastem Verastem
VSTM
$ 5.04 -4.73 % $ 349 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 3.96 -4.12 % $ 232 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.57 -5.87 % $ 17.6 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 12.41 -11.1 % $ 1.88 B usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 6.37 2.66 % $ 1.07 B singaporeSingapore
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 2.72 -2.86 % $ 4.63 M usaUSA
XBiotech XBiotech
XBIT
$ 2.27 -1.73 % $ 69.2 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 54.48 -1.89 % $ 4.24 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 5.4 -3.05 % $ 866 M usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 4.04 -6.26 % $ 171 M usaUSA
Xencor Xencor
XNCR
$ 11.42 -7.23 % $ 848 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
$ 30.17 -1.18 % $ 364 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
22nd Century Group 22nd Century Group
XXII
$ 2.41 -18.03 % $ 444 K usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 18.0 2.8 % $ 19.7 B chinaChina
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.05 -3.67 % $ 21.5 M israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA